Anti-Oxidized Macrophage Migration Inhibitory Factor (oxMIF) Antibody Imalumab (BAX69) in Advanced Solid Tumors: Final Results of First-In-Human Phase 1 Study

Annals of Oncology - United Kingdom
doi 10.1093/annonc/mdw368.08
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Phase I First-In-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2015English

A Phase 1 Study of Anti-TGFβ Receptor Type-Ii Monoclonal Antibody LY3022859 in Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2017English

First-In-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-Her3 Monoclonal Antibody, in Patients With Metastatic or Advanced HER3-Positive Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2015English

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2014English

Phase I Study of Nivolumab, an Anti-Pd-1 Antibody, in Patients With Malignant Solid Tumors

Investigational New Drugs
OncologyPharmacology
2016English

First-In-Human Phase 1 Trial of Agarose Beads Containing Murine RENCA Cells in Advanced Solid Tumors

Cancer Growth and Metastasis
2016English

A Phase I First-In-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients With Advanced Cancer

Clinical Cancer Research
Cancer ResearchOncology
2012English

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy